Navigation Links
New Study on Cordyceps Sinensis (Hirsutella Sinensis) Shows Anti-Inflammatory Properties
Date:4/30/2013

Los Angeles, CA (PRWEB) April 30, 2013

Cordyceps sinensis is a medicinal fungus used for centuries in Asian countries as a health supplement and tonic. Traditionally prescribed by medical practitioners as a kidney and lung supplement, studies have found Cordyceps Sinensis’ impact on the human body reaches other functions as well, such as energy, fertility and anti-inflammation.*

Published in the March 5, 2013 issue of Scientific Journal, a new study details findings revealing Cordyceps Sinensis’ anti-inflammatory properties. These benefits were attributed to Cordyceps Sinensis’ ability to inhibit both canonical and non-canonical inflammasomes. Inflammasomes have been associated with several auto-inflammatory conditions such as gout. This study, performed at the Center for Molecular and Clinical Immunology at Chang Gung University in Taiwan, documents Cordyceps Sinensis’ suppression of interleukin-1ß and interleukin-18 secretion.

The study uses a specific anamorphic mycelial form of Cordyceps Sinensis known as Hirsutella Sinensis. This specific strain has proven to be rare and difficult to cultivate. Through Molecular Germplasm Identification, this particular strain of Cordyceps Sinensis' rDNA sequence matches wild-grown Cordyceps Sinensis by 99.645%, proving authenticity. Other strains on the market match only by 82.791%.

Download Cordyceps Sinensis (Hirsutella Sinensis) Clinical Trial

How to cite the study: Huang, T. et al. Hirsutella sinensis mycelium suppresses interleukin-1b and interleukin-18 secretion by inhibiting both canonical and non-canonical inflammasomes. Sci. Rep. 3, 1374; DOI:10.1038/srep01374 (2013).

*Legal Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Read the full story at http://www.prweb.com/releases/cordyceps-sinensis/hirstuella-sinensis/prweb10684567.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. New Study: Valtrex (Valacyclovir) Side Effects Target the Brain; polyDNA Suggests a Natural Herpes Remedy
2. Wysebridge Patent Bar Review Launches America Invents Act (AIA) Study Suite
3. Breath study brings roadside drug testing closer
4. Japan Bioinformatics Announces Release of a Case Study on Detecting SNPs and Short INDELs
5. Research Foundations Collaborate To Fund Phase 1 Study Of Cancer Drug In Alzheimers Disease Patients
6. Ceregene Reports Data From Parkinsons Disease Phase 2b Study
7. Study Says Kidney Bean Leaves Work Against Bed Bugs, My Cleaning Products Compares Its With a Non-Pesticide Bed Bug Spray
8. NeuroDerm Announces Enrollment in a Phase 2 Study of ND0612, a Continuous Levodopa/Carbidopa Drug for the Treatment of Parkinsons Disease
9. A bright idea: Tiny injectable LEDs help neuroscientists study the brain
10. Study Says Bed Bugs Show Resistance to Pesticides, My Cleaning Products Asserts Non-Pesticide Bed Bug Bully Is the Better Pick Against the Pests
11. Inflamax Research Chosen to Conduct a Multicenter Environmental Exposure Chamber Phase 3 Study of Ultrashort Grass Allergy Vaccine by Allergy Therapeutics (UK) Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... 2016 /PRNewswire/ - Portage Biotech Inc. ("Portage" or "the ... excited to announce the formation of EyGen, Ltd. ... ophthalmology assets through proof of concept. EyGen,s lead ... Portage Pharmaceuticals Limited and being developed for topical ... anterior segment diseases. This agent has the potential ...
(Date:11/30/2016)...  The Allen Institute for Cell Science has ... available collection of gene edited, fluorescently tagged human ... structures with unprecedented clarity. Distributed through the Coriell ... a crucial first step toward visualizing the dynamic ... human cells healthy and what goes wrong in ...
(Date:11/30/2016)... , Nov. 30, 2016  Tempus, a technology ... care, and Penn,s Abramson Cancer Center have partnered ... positive response to immunotherapy treatment based on next ... As part of a research collaboration, Tempus will ... melanoma cancer patient data to Penn. Utilizing next-generation ...
(Date:11/30/2016)... , 30. November 2016   ... hat heute die Unterzeichnung einer Reihe von ... zufolge wird Evotec AG Screeningleistungen für Mercks ... bereitstellen. Der Zugriff auf diese Bibliotheken in ... eröffnet einen schnelleren Weg zur Ermittlung und ...
Breaking Biology Technology:
(Date:6/21/2016)... VANCOUVER, British Columbia , June 21, 2016 ... been appointed to the new role of principal ... has been named the director of customer development. ... , NuData,s chief technical officer. The moves reflect ... development teams in response to high customer demand ...
(Date:6/15/2016)... ALBANY, New York , June 15, 2016 ... published a new market report titled "Gesture Recognition Market ... Trends and Forecast, 2016 - 2024". According to the ... at USD 11.60 billion in 2015 and is ... and reach USD 48.56 billion by 2024.  ...
(Date:6/7/2016)... -- Syngrafii Inc. and San Antonio Credit Union (SACU) ... Syngrafii,s patented LongPen™ eSignature "Wet" solution into SACU,s ... in greater convenience for SACU members and operational ... document workflow and compliance requirements. Logo ... Highlights: ...
Breaking Biology News(10 mins):